autologous cd34+ cell-enriched population that contains cells transduced with lenti-d lentiviral vector that encodes an abcd1 cdna
Cell therapyexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Sep 30, 2011 (NCT01355224)
Timeline
Indications
Mechanism of action
- Unspecified targetTissue restoration
tissue restoration
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06042452 | N/A | Jan 31, 2024 | FitnessGenes Ltd. |
| NCT04489134 | Phase 2 | Sep 30, 2020 | University of Rennes |
| NCT03852498 | Phase 3 | Jan 24, 2019 | bluebird bio |
| NCT01355224 | N/A | Sep 30, 2011 | Boston University, National Human Genome Research Institute (NHGRI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| bluebird bio | For profit | 1 | 1 | 1 | 2019 |
| Boston University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| FitnessGenes Ltd. | For profit | 1 | 1 | 1 | 2024 |
| National Human Genome Research Institute (NHGRI) | Government | 1 | 0 | 1 | 2011 |
| University of Rennes | Academic/Hospital | 1 | 1 | 1 | 2020 |
5 organizations
Page 1 / 1